✨ Free AI Report
Alterity Therapeutics Ltd: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Alterity Therapeutics Ltd
Company Research

Alterity Therapeutics Ltd: Business Overview, Financials & Competitive Analysis

Alterity Therapeutics Ltd scores 6/10 on the AskCyborg Cyborg Score (Solid). Rare-disease biotech with lead asset showing clinical promise in unmet-need MSA market; Phase 3 initiation and FDA alignment de-risk path to potential approval. Alterity has successfully advanced ATH434 through Phase 2 with positive efficacy signals in an unmet indication and received FDA clearance to proceed to Phase 3 as.

What is Alterity Therapeutics Ltd's industry? Alterity Therapeutics Ltd (alteritytherapeutics.com) operates in Neurology Drugs. AskCyborg classifies Alterity Therapeutics Ltd under Neurology Drugs in its company registry.

Alterity Therapeutics is a clinical stage biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, focused on Multiple System Atrophy (MSA) and related Parkinsonian di...

6/ 10Solid

Cyborg Score thesis

Rare-disease biotech with lead asset showing clinical promise in unmet-need MSA market; Phase 3 initiation and FDA alignment...

Read the full analyst-debate transcript →
Industry Neurology Drugs
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Alterity Therapeutics Ltd Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Alterity Therapeutics Ltd

AskCyborg analysts argue the bull and bear cases for Alterity Therapeutics Ltd across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Alterity Therapeutics Ltd OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Alterity Therapeutics Ltd Overview

Pro stress-test →

Alterity Therapeutics is a clinical stage biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, focused on Multiple System Atrophy (MSA) and related Parkinsonian disorders. Results from Phase 2 trials demonstrated the drug to be safe and well-tolerated with strong signals of efficacy in an indication that currently has no approved disease-modifying treatments available.

Strategic Profile

Pro stress-test →

The lead asset ATH434 has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA and positive data in an open label Phase 2 trial in advanced MSA, with the company preparing to initiate a Phase 3 pivotal trial in MSA while developing a broader pipeline of compounds targeting neurological disease pathology. As of July 7, 2026, the company received official minutes from its End-of-Phase-2 meeting with the FDA regarding ATH434.

Competitive Landscape

Pro stress-test →

Alterity operates in the rare neurodegenerative disease space where few approved therapies exist for MSA. Potential competitors include other biotech firms developing Parkinsonian disorder treatments and broader neurodegeneration programs, though MSA remains underserved with limited direct competition for this specific indication.

Industry Context

Alterity Therapeutics Ltd operates in Neurology Drugs.

Key facts

Founded: N/A · Headquarters: Melbourne, Australia (with US operations in San Francisco) · Employees: N/A · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Alterity Therapeutics Ltd.

  • ATH434 addresses Multiple System Atrophy, a rare neurodegenerative disease with no approved disease-modifying treatments, representing a significant unmet medical need
  • Phase 2 data demonstrated both safety and efficacy signals in randomized controlled and open-label trials, supporting progression to Phase 3 pivotal trial
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2026ATH434 presented late-breaker oral presentation at American Academy of Neurology Annual Meeting demonstrating disease-modifying signal using MuSyCA Composite Scale
  • May 2026Multiple System Atrophy program data presented at major medical conferences including ISMRM, MDSANZ, and MSA Symposium 2026
  • +1 moreTrack every material event for Alterity Therapeutics Ltd as it happens. Explore monitoring →
Get alerted when Alterity Therapeutics Ltd has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Biogen ADUHELM / Amyloid-targeting programsNeurodegenerative disease and neuroinflammatory programs→Eli Lilly Neurodegenerative PortfolioNeurodegeneration and Alzheimer's disease programs→Biohaven PharmaceuticalsNeuroinflammation inhibitor development for neurodegeneration→NeurogeneGene therapy for neurological and neurodegenerative disorders→

Compare Alterity Therapeutics Ltd with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Alterity Therapeutics Ltd operates in Neurology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Neurology Drugs research →
NEW · MCP server

Ask your AI assistant about Alterity Therapeutics Ltd

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Alterity Therapeutics Ltd and its top competitor on Cyborg Score”
“What did Alterity Therapeutics Ltd do this quarter?”
“Is Alterity Therapeutics Ltd a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Alterity Therapeutics Ltd do?+
Alterity Therapeutics is a clinical stage biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, focused on Multiple System Atrophy (MSA) and related Parkinsonian di...
What is Alterity Therapeutics Ltd's Cyborg Score?+
Alterity Therapeutics Ltd has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Alterity Therapeutics Ltd's main competitors?+
Named competitors include Biogen ADUHELM / Amyloid-targeting programs, Eli Lilly Neurodegenerative Portfolio, Biohaven Pharmaceuticals, Neurogene. The full competitive landscape is in the AskCyborg report.
How can I get the full Alterity Therapeutics Ltd research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Alterity Therapeutics Ltd research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Alterity Therapeutics Ltd over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Neurology Drugs research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Neurogene Inc.